drugset
drugset / Trial / NCT05749055

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

NCT05749055 ↗

Phase 2 Completed 252 enrolled Engrail Therapeutics INC
RandomizedParallel-groupTriple-blindTreatment

Summary

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Timeline

Start
2023-07-03
Primary completion
2025-09-18
Completion
2025-09-18

Drugs

EvaluationDrugModalityDoseRoute
Subject ENX-102 Unknown 2 mg Oral

Indications

generalized anxiety disorder